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Abstract
Objective. To determine the impact of physiologic changes of pregnancy on pharmacokinetics of chemotherapeutic agents.
Design. A preclinical and a clinical case–control trial. Setting. Institute of Primate Research Nairobi and collaborating hospitals
in Belgium, the Netherlands and Czech Republic. Population. Pregnant and nonpregnant women and baboons receiving
chemotherapy. Methods. Chemotherapy pharmacokinetics was compared between the pregnant and nonpregnant state.
Standard-dosed chemotherapy regimens were administered in pregnant and nonpregnant baboons/women, followed by
serial blood samplings. Drug plasma levels were determined using high performance liquid chromatography and atomic
absorption spectrometry. Main outcome measures. Area under the curve (AUC), maximal plasma concentration, terminal
elimination half-life, clearance and distribution volume of each drug in pregnant and nonpregnant state.Results. Intraindividual
comparative pharmacokinetic data were obtained for doxorubicin and paclitaxel/platinum in three and two baboons,
respectively. In the clinical trial, two patients were exposed to doxorubicin and one patient was exposed to paclitaxel/
platinum during and after pregnancy. Furthermore, a pooled analysis was performed based on 16 cycles of pregnant and
11 cycles of nonpregnant women. Numbers of pregnant/nonpregnant patients were 5/2, 7/5, 4/4 and 2/2 for paclitaxel,
doxorubicin, epirubicin and platinum, respectively. For all drugs tested in the preclinical and clinical study, a decreased AUC
and maximal plasma concentration and an increased distribution volume and clearance were observed in pregnancy.
Conclusions. Although numbers were too small for statistical signiﬁcance, pregnancy-associated physiologic alterations appear
to lead to a decrease in plasma exposure of chemotherapeutic drugs. The importance of long-term follow-up of women treated
with chemotherapy during pregnancy is underscored.
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Introduction
Most anticancer drugs exhibit a narrow therapeutic
window with small margins between toxic and thera-
peutic exposure. Interindividual pharmacokinetic and
pharmacodynamic variability is usually substantial and
may be augmented by pregnancy (1). During preg-
nancy multiple changes in physiology occur affecting
themajor pharmacokinetic processes including absorp-
tion, distribution, metabolism and excretion (2).
The distribution volume of drugs may be increased
during pregnancy as a result of the increase in extra-
cellular ﬂuid volume and plasma volume expansion by
50%. As pregnancy advances, the plasma volume
expands at a higher rate than the increase in albumin
production, creating a dilutional hypoalbuminemia,
which might increase the fraction of unbound drugs
(3). Increased secretion of estrogen and progesterone
during normal pregnancy can induce or inhibit
hepatic drug metabolism. This cholestatic effect of
estrogen may interfere with biliary drug clearance.
Increased renal blood ﬂow and glomerular ﬁltration
during pregnancy may result in increased renal elim-
ination (3).
In the absence of valid data, currently the same
dosing regimens are administered in pregnant and
nonpregnant women. However, due to the lack of
prospective controlled studies exploring relations
between dose-pharmacokinetics and pharmacody-
namics during pregnancy it is unknown whether the
pregnant patient is treated optimally with standard
chemotherapy regimens as applied in current clinical
practice to patients in the nonpregnant state (4,5).
Therefore, we initiated a study examining pharma-
cokinetic parameters of cytotoxic drugs in pregnancy.
Firstly, we designed a pregnant baboon model to test
gestational effects on pharmacokinetics. Because of
the close phylogenetic relation between humans and
nonhuman primates, the reproductive physiology and
endocrinology of pregnancy and drug metabolism are
very similar, allowing extrapolation of data to the
human setting (6).
Secondly, a clinical study was performed to
compare pharmacokinetic parameters between the
pregnant and nonpregnant state intra- and
interindividually.
Material and methods
Accrual and drugs in the baboon study
The study protocol was approved by the Institutional
Scientiﬁc and Ethical Review Committee of the Insti-
tute of Primate Research, Nairobi, Kenya. Animals
were treated according to guidelines for Good Lab-
oratory Practices.
This study was part of a project investigating the
transplacental transfer and pharmacokinetics of che-
motherapeutic agents in baboon model. In total
19 animals were used for the investigation of trans-
placental transfer of chemotherapy, in ﬁve of them a
series of maternal blood samples also were collected
over the ﬁrst 24 hours after drug infusion for phar-
macokinetic analysis. In these ﬁve baboons, an iden-
tical administration and sampling scheme was applied
once more at least 40 days postpartum. This moment
was chosen since hemodynamic changes are known to
return to pre-pregnant baseline within 6 weeks fol-
lowing delivery.
After capturing the baboons (Papio anubis), physical
examinations and infectious screenings were per-
formed and 3 months of quarantine were completed.
Animals were timed-mated based on daily recording
of the changes in the perineal sex skin as previously
described (7). The baboons were housed in single
cages, except for the period of timed mating, and were
fed on a daily diet of high protein pellets.
Combination regimens of chemotherapeutic
drugs were administered under general anesthesia.
Therefore, animals were sedated with an intramus-
cular injection of ketamine 10 mg/kg and xylazine
0.5 mg/kg and endotracheally intubated. General
anesthesia was induced with halothane, nitrous
oxide and oxygen. Chemotherapy was administered
through a femoral vein catheter (20 G). The contra-
lateral femoral vein was catheterized for serial blood
samplings. A urinary catheter (10 Ch) was used for
urine drainage. When chemotherapy administration
was completed, the animals were placed in a restrain
chair for 12 or 24 hours, allowing further blood
samplings.
The tested drug regimens included a combination
of doxorubicin (25 mg/m2), bleomycin (10 mg/m2),
vinblastine (6 mg/m2) and dacarbazine (375 mg/m2)
(ABVD) and a combination of paclitaxel (175 mg/m2)
and carboplatin. For carboplatin, the dosage was
determined according to the Calvert’s formula
(dose = target area under the curve (AUC)  (glo-
merular ﬁltration rate + 25)) (8) with a target AUC
of 6. Glomerular ﬁltration rate was estimated based
on the Schwartz formula (0.55  height (cm)/serum
creatinine (mg/dl)  (body surface area/1.73). Drug
administration occurred in a similar way as in clinical
practice, including premedication with alizapride, and
for paclitaxel-including regimens also cetirizine, solu-
medrol and ranitidine were used.
Carboplatin (Carbosin), doxorubicin (Doxoru-
bicin), bleomycin (Bleomin), dacarbazin (Dacar-
bazine), vinblastine (Vinblastin) and paclitaxel
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(Paxene) were kindly provided by Teva Pharma
Belgium NV, Wilrijk, Belgium.
Accrual and drugs in the clinical study
Pregnant patients diagnosed with cancer necessitat-
ing chemotherapy were identiﬁed in an international
collaborative setting. Postpartum and nonpregnant
matched women constituted the control group.
The study was approved by the institutional review
board in all participating centers, including University
Hospital Gasthuisberg Leuven, University Hospital
Gent, General Hospital Jan Palﬁjn Brugge, General
Hospital St Jozef Turnhout in Belgium and Radboud
University Medical Centre in Nijmegen, University
Medical Center Utrecht and Catharina Hospital
Eindhoven in The Netherlands and the Motol Hos-
pital Prague in the Czech Republic.
Informed consent was obtained from all patients in
accordance with institutional regulations.
Patients received standard regimens of combina-
tion chemotherapy as currently applied in the disease-
speciﬁc oncological treatment of nonpregnant women
(ABVD: Doxorubicin, Bleomycin, Vinblastine,
Dacarbazine; (F)AC: (5-Fluorouracil), Doxorubicin,
Cyclophosphamide; FEC: 5-Fluorouracil, Epirubi-
cin, Cyclophosphamide; (R-)CHOP: (Rituximab),
Cyclophosphamide, Doxorubicin, Vincristine, Pred-
nisolone; Paclitaxel +/ Carboplatin or Cisplatin).
Dosage was body surface area-based for most drugs.
Only carboplatinum dosage was determined based on
the creatinine clearance, according to the Calvert’s
formula (8). Glomerular ﬁltration rate was estimated
basedontheCockroft formula: ((140–age (y))weight
(kg)  0.85)/(72  serum creatinine (mg/dl)) (9).
Blood sample collection
From the start of the drug infusion, blood samples
were collected over 24 hours in the baboon study and
over 48 hours in the clinical study. For short infusions
(<90¢), the ﬁrst sample was collected at the end of the
infusion of interest. Subsequently target sampling
times were 15 and 30 minutes and 1, 2, 4, 6, 8,
12, 24 and 48 hours after the end of the drug infusion.
For longer infusions (>90¢), also during drug infusion,
a blood sample was collected every hour. Whenever
sampling times varied, this was noted. Variability was
due to overlap when two drugs were tested in a
combination scheme, and technical difﬁculties to
withdraw blood.
Blood samples were collected in EDTA-tubes and
centrifuged (3,000 rpm, 4C, 10 minutes) within
2 hours. Plasma was stored at 80C until analysis.
Drug analysis
Levels of doxorubicin, epirubicin and paclitaxel were
determined in plasma by high performance liquid
chromatography. Total platinum was determined
using atomic absorption spectrometry.
Doxorubicin and epirubicin were determined in
plasma by high performance liquid chromatography.
Drugs were extracted from plasma at pH 9.0 with
borate buffer and a chloroform-2-propanol mixture
(85/15, v/v). Calibration curves were constructed in
the blank plasma. Chromatographic analysis was car-
ried out by reversed-phase isocratic elution on a high
performance liquid chromatography column ﬁlled
with Hypersil BDS 5 m (250  4.6 mm I.D.) with
a mobile phase mixture of acetonitrile and potassium
phosphate buffer 15 mM pH 3.0 (+0.05% triethyla-
mine) (25/75, v/v). For doxorubicin determination,
epirubicin was used as internal standard. For epiru-
bicin determination doxorubicin was used as internal
standard.
Detection was accomplished by ﬂuorometry with
a Waters 2475 ﬂuorescence detector at excitation
and emission wavelengths of 480 and 560 nm,
respectively.
The method was linear over a concentration range
of 2.5–1,000 ng/ml for doxorubicin and epirubicin.
The average recoveries of doxorubicin and epiru-
bicin from plasma were 78.3 ± 7.6% (mean ± SD) and
79.0 ± 12.1%, respectively. The lower limit of quan-
tiﬁcation was 2.5 ng/ml and the method proved to be
precise and accurate, as the intra- and interday coefﬁ-
cients of variation were less than 15%.
Paclitaxel was determined in plasma by high per-
formance liquid chromatography after plasma extrac-
tion with a mixture of hexane and ethylacetate (50/50,
v/v), buffered with ammoniumacetate 0.1 M pH 5.
For paclitaxel determination docetaxel was used as
internal standard. Calibration curves were con-
structed in the blank plasma.
Separation of paclitaxel was performed on a
reversed-phase column packed with Novapack C8
4 m, using a mobile phase mixture of acetonitrile
and 20 mM ammoniumacetate buffer pH 5 (40/60,
v/v) at a ﬂow rate of 1 ml/minute and UV detection at
227 nm.
Linearity of the calibration curves for paclitaxel was
found in the range of 25–5,000 ng/ml. The lower limit
of quantiﬁcation for paclitaxel was 25 ng/ml, being the
lowest concentration of the standard curve with a
coefﬁcient of variation lower than 20%. Analytical
recovery (%) of paclitaxel from plasma was 101.0 ±
11.7 (mean ± SD). Coefﬁcients of variation for intra-
and interday precision and accuracy were all below
15%.
1340 K. Van Calsteren et al.
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For the determination of total platinum, plasma
samples were diluted six times in water and 20 ml of
the solution was injected in the atomic absorption
spectrometer with pyrocoated graphite tube and cath-
ode Pt-lamp (Zeeman/3030, Perkin-Elmer, Shelton,
USA). Quantiﬁcation was performed with a calibra-
tion curve (matrix matched), which was linear over
the range 178–1,048 mg/L with a coefﬁcient of vari-
ation of 6.2%. The detection limit was 10 mg/L.
Pharmacokinetic data analysis
Pharmacokinetic analysis was performed using Win-
NonLin (Pharsight, Mountain View, CA) with the
non-compartmental, linear up log down application.
Cmax indicates the maximal plasma concentration.
Terminal elimination half-life (t1/2) was calculated
from the slope (l) of the linear regression analysis
over the (semi-logarithmic) last four plasma concen-
tration versus time points: t1/2 = ln 2/l. AUC was
calculated by the trapezoidal method with extrapola-
tion to inﬁnity. Total body clearance (Cl) was calcu-
lated by the formula: Cl = Dose/AUC; and
distribution volume (Vd) by: Vd = Cl/l.
For the comparison of results, Cmax and AUC were
corrected for dose and infusion time (CmaxD IT)
and for dose (AUC  D), respectively.
Statistics
Data are shown in mean + SD. Because of the small
number of baboons, no statistical analysis was per-
formed on the preclinical data. For the clinical study,
statistical testing was performed with Graphpad Prism
5 (GraphPad Software, Inc., La Jolla, CA, USA).
Given the small numbers, a non-parametric two-sided
Wilcoxon rank-sum test was applied to compare con-
tinuous variables in two groups. Results were consid-
ered signiﬁcant at p < 0.05.
Results
Baboon study
Five baboons received an identical regimen of che-
motherapy once during pregnancy (mean gestational
age 142 + 9 days) and once during postpartum (56 +
11 days postpartum). The mean height of the animals
was 95.6 + 1.4 cm, the mean weight during pregnancy
was 16.1 + 1.0 kg and the weight postpartum was
14.3 + 1.5 kg.
Three baboons received doxorubicin, two baboons
were exposed to the combination of paclitaxel and
carboplatin (Table 1).
Table 2 shows the pharmacokinetic parameters of
doxorubicin obtained in pregnant and postpartum
baboons. Comparison of the results revealed a similar
pattern in the three tested animals. Cmax  D was
remarkably lower during pregnancy (39% reduction),
as well as AUC  D and t1/2 (42 and 32% reduction,
respectively). Drug clearance was 77% higher during
pregnancy. Compared to postpartum values, an 18%
increase in distribution volume was noted during
pregnancy (Table 2).
In Table 3, the pharmacokinetic parameters
for paclitaxel and platinum are presented. In
PAN2656, no blood sample was available exactly at
the end of the platinum infusion. As a result Cmax and
AUC could not be determined. The results between
both animals varied substantially. However, both
revealed a lower Cmax  D, a lower AUC  D,
and an increased clearance, t1/2 and distribution vol-
ume during pregnancy (Table 3).
Clinical study
In total 16 cycles from pregnant patients were avail-
able and 11 from nonpregnant women (4 postpartum,
7 not related to pregnancy). Patient characteristics
Table 1. Overview of baboon characteristics and drug infusion schemes.
Baboon Drug
Gestational
state (days) BSA Dose (mg) IT (hour)
GA PP GA PP Pr PP Pr PP
PAN2044 Doxorubicin 25 mg/m2a 157 40 0.64 0.58 15.5 14.5 0.3 0.3
PAN2596 Doxorubicin 25 mg/m2a 146 57 0.67 0.60 16.6 15.0 0.3 0.4
PAN3072 Doxorubicin 25 mg/m2a 137 67 0.61 0.60 15.2 15.0 0.3 0.3
PAN2656 Paclitaxel 175 mg/m2 139 65 0.66 0.64 115.0 112.0 3.0 3.0
Carboplatin AUC6 244.0 266.0 1.0 1.0
PAN3068 Paclitaxel 175 mg/m2 133 49 0.67 0.65 117.0 114.0 2.0 2.0
Carboplatin AUC6 263.0 282.0 0.5 0.5
aAdministered in combination with bleomycin, dacarbazine and vinblastine.
Note: GA, gestational age; BSA, body surface area; Pr, pregnant; PP, postpartum; IT, infusion time; AUC, area under the curve.
Reduced chemotherapy exposure in pregnancy 1341
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and chemotherapy regimens are presented in Table 4.
Numbers of pregnant/nonpregnant patients treated
were 5/2, 7/5, 4/4, 2/2 for paclitaxel, doxorubicin,
epirubicin and carboplatin, respectively.
Intrapatient comparison of the most important
pharmacokinetic parameters for doxorubicin, pacli-
taxel and carboplatin in patients receiving the same
chemotherapy regimen during and after pregnancy
(n = 3) is shown in Table 5. During pregnancy, an
increased distribution volume and clearance were
seen, resulting in a decreased AUC and Cmax. For
carboplatin and paclitaxel, the differences were less
pronounced than for doxorubicin. In this patient the
postpartum values were obtained 4 weeks after the
delivery, which might be too short to exclude any
impact of the pregnancy.
Table 6 shows the comparison of the pooled data of
pregnant versus control patients for paclitaxel, carbo-
platin, doxorubicin and epirubicin. The data obtained
show similar changes for all tested chemotherapeutic
drugs. During pregnancy the distribution volume and
clearance increased while the AUC  D and
Cmax  D  IT decreased.
Discussion
To the best of our knowledge, the impact of the
pregnant state on the pharmacokinetics of cytotoxic
drugs has not been studied in vivo in nonhuman
primates or in humans yet. In a preclinical study in
baboons, we tested the hypothesis that gestational
alterations affect drug disposition resulting in a
reduced plasma exposure to cytotoxic drugs after
standard dosing. This ﬁnding was conﬁrmed in a
clinical study with analysis of intraindividual and
pooled patient data. Therefore, it cannot be excluded
that cytotoxic drug efﬁcacy is also impaired during
pregnancy. Overall, these data underscore the impor-
tance of long-term follow-up with regard to overall
survival of women treated with chemotherapy during
pregnancy.
To date, only one case report of paclitaxel phar-
macokinetics during pregnancy has been reported,
showing a decreased Cmax and AUC during preg-
nancy (10). This ﬁnding is conﬁrmed in the current
series.
As gestational changes in physiology are known to
affect drug disposition in general, they can also alter
exposure to chemotherapeutics (3). Consequently,
these changes can result in subtherapeutic or toxic
drug levels. Obviously, these situations should be
prevented, particularly in oncology where patients
are treated with potent, mutagenic and teratogenic
chemotherapeutics.
The clinical impact of our ﬁndings may be consid-
erable. Cytotoxic drugs during pregnancy are mostly
administered for primary cancer treatment. In addi-
tion to surgery and/or radiotherapy, systemic cancer
treatment adds to local and systemic tumor control.
Table 2. Comparison of pharmacokinetic parameters of doxorubicin between pregnant and postpartum baboons.
Baboon: PAN2044 PAN2596 PAN3072
Mean
Pr/PPPK parameter Pr PP Pr/PP Pr PP Pr/PP Pr PP Pr/PP
Cmax  D (ng/ml/mg) 56.3 94.5 0.60 87.4 152.3 0.57 87.2 131.4 0.66 0.61 ± 0.05
AUC  D (hourng/ml/mg) 29.7 43.7 0.68 36.6 77.6 0.47 34.8 60.3 0.58 0.58 ± 0.11
t1/2 (hour) 9.3 11.4 0.82 16.3 26.8 0.61 10.2 16.6 0.61 0.68 ± 0.12
Clearance (L/hour) 33.7 22.9 1.47 27.3 12.9 2.12 28.7 16.6 1.73 1.77 ± 0.33
Vd (L) 449.9 375.7 1.20 640.3 499.2 1.28 421.0 399.9 1.05 1.18 ± 0.12
Note: PK, pharmacokinetic; Cmax  D, the maximum concentration corrected for dose; AUC  D, area under the curve corrected for dose;
t1/2, terminal half-life; Vd, distribution volume.
Table 3. Comparison of pharmacokinetic parameters of paclitaxel and platinum between pregnant and postpartum baboons.
Drug Paclitaxel Platinum
Baboon PAN2656 PAN3068
Mean
Pr/PP
PAN2656 PAN3068
Mean
Pr/PPPK parameter Pr PP Pr/PP Pr PP Pr/PP Pr PP Pr/PP Pr PP Pr/PP
Cmax  D (mg/ml/mg) 73.1 271.0 0.27 126.9 184.7 0.69 0.48 ± 0.30 82.0 107.4 163.5 0.66 0.66
AUC  D (hourmg/ml) 288.6 713.3 0.40 412.5 446.4 0.92 0.66 ± 0.37 310.9 316.2 434.5 0.73 0.73
t1/2 (hour) 4.5 4.1 1.10 4.6 2.8 1.64 1.37 ± 0.38 51.9 40.8 1.27 13.7 7.8 1.76 1.52 ± 0.35
Clearance (L/hour) 3.5 1.4 2.50 2.4 2.2 1.09 1.80 ± 1.00 4.2 3.2 1.31 3.2 2.3 1.39 1.35 ± 0.06
Vd (L) 22.7 8.3 2.73 16.1 9.1 1.77 2.25 ± 0.68 311.2 189.5 1.64 62.6 26.0 2.41 2.03 ± 0.54
Note: PK, pharmacokinetic; Cmax  D, the maximum concentration corrected for dose; AUC  D, area under the curve corrected for dose;
t1/2, terminal half-life; Vd, distribution volume.
1342 K. Van Calsteren et al.
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Table 4. Patient characteristics, chemotherapy and dosing schedule.
Pt
Age
(year) Malignancy
GA
(week)
Control
samples
BSA
(m2) Chemotherapy Tested drug
Dosage
(mg/m2)
1 32 Breast 31 2.14 FAC Doxorubicin 65
61 d PP 2.05 TAC Doxorubicin 50
2 34 Breast 31 1.80 FAC Doxorubicin 60
3 32 Breast 31 2.00 AC Doxorubicin 60
49 d PP 1.87 AC Doxorubicin 60
4 26 Breast 29 1.78 FAC Doxorubicin 50
31 1.79 Paclitaxel Paclitaxel 175
5 34 Breast 32 1.83 AC Doxorubicin 60
6 34 Breast 32 1.74 AC Doxorubicin 60
7 17 Hodgkin NP 1.71 ABVD Doxorubicin 25
8 54 Hodgkin NP 1.68 ABVD Doxorubicin 25
9 32 NHL 22 1.65 CHOP Doxorubicin 50
44 d PP 1.70 R-CHOP Doxorubicin 50
10 40 Breast 31 1.92 FEC Epirubicin 100
11 33 Breast 30 2.33 FEC Epirubicin 75
12 36 Breast 19 1.85 FEC Epirubicin 100
13 36 Breast 32 1.88 FEC Epirubicin 100
14 48 Breast NP 1.53 FEC Epirubicin 100
15 35 Breast NP 1.70 FEC Epirubicin 100
16 31 Breast NP 1.66 FEC Epirubicin 100
17 31 Breast NP 1.59 FEC Epirubicin 100
18 36 Ovarian 29 1.75 Paclitaxel–Cisplatin Paclitaxel 175
19 34 Ovarian NP 1.66 Paclitaxel–Carboplatin Paclitaxel 175
Carboplatin AUC6
20 36 Ovarian 23 1.93 Paclitaxel Paclitaxel 175
21 28 Ovarian 23 1.77 Paclitaxel–Carboplatin Paclitaxel 175
Carboplatin AUC5
30 d PP 1.83 Paclitaxel–Carboplatin Paclitaxel 175
Carboplatin AUC5
22 34 Cervical 25 1.93 Paclitaxel–Carboplatin Paclitaxel 175
Carboplatin AUC5
Note: GA, gestational age; d, days; PP, postpartum; NP, nonpregnant; NHL, non-Hodgkin lymphoma; ABVD, Doxorubicin, Bleomycin,
Vinblastine, Dacarbazine; (F)AC, (5-Fluorouracil), Doxorubicin, Cyclophosphamide; FEC, 5-Fluorouracil, Epirubicin, Cyclophosphamide;
(R-)CHOP, (Rituximab), Cyclophosphamide, Doxorubicin, Vincristine, Prednisolone.
Table 5. Intraindividual comparison of the most important pharmacokinetic parameters of doxorubicin, paclitaxel and carboplatin during
pregnancy and postpartum.
Drug Pt
Time
(week)
BSA
(m2)
t1/2
(hour)
Cmax  D  IT
(ng/mlmghour) Vd (L)
Clearance
(L/hour)
AUC  D
(hourng/ml/mg)
Doxorubicin 3 Pr 31 2.00 32.41 7.47 3,066.68 65.59 15.25
PP 7 1.87 33.05 9.85 1,574.92 33.03 30.28
Pr/PP 1.07 0.98 0.76 1.95 1.99 0.50
9 Pr 22 1.65 20.99 a 2,356.43 77.82 12.85
PP 6.5 1.70 25.83 10.15 1,813.23 48.66 20.55
Pr/PP 0.97 0.81 1.30 1.60 0.63
Paclitaxel 21 Pr 23 1.77 9.41 32.09 391.94 28.86 34.65
PP 4 1.83 13.92 38.20 537.57 26.77 37.36
Pr/PP 0.96 0.68 0.84 0.73 1.08 0.93
Carboplatin 21 Pr 23 1.77 29.84 10.64 432.81 10,053.04 99.47
PP 4 1.83 21.91 10.68 271.83 8,600.11 116.28
Pr/PP 0.96 1.36 1.00 1.59 1.17 0.86
aSample was not collected exactly at the end of the infusion, and therefore Cmax is considered unreliable.
Note: Pr, pregnant; PP, postpartum; BSA, body surface area; IT, infusion time; CmaxD IT, maximal concentration corrected for dose and
infusion time; Vd, distribution volume; AUC  D, area under the curve corrected for dose.
Reduced chemotherapy exposure in pregnancy 1343
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The observed alterations in systemic exposure to
chemotherapeutic drugs during pregnancy may
reduce therapeutic efﬁcacy. Currently, there are no
indications suggesting that patients with cancer when
treated during pregnancy with standard height–weight
based dosed chemotherapy are at higher risk of
reduced efﬁcacy or more toxicity compared to non-
pregnant patients (11,12). However, the conclusion
that the prognosis is not worse for pregnant women
deserves a critical note. In the available studies, the
number of patients per tumor type does not allow
controlling for the assessed treatment and speciﬁc
prognostic markers. Moreover, the reported results
are based on a relative short follow-up period (11,12).
Our study indicates that the subgroup necessitating
chemotherapy deserves special attention. Although
the existing data are reassuring, only larger series
with sufﬁcient follow-up can determine the impact
of pregnancy on maternal outcome.
Two pharmacokinetic aspects can be the reason
why pregnancy might not necessarily worsen the
prognosis when chemotherapy is administered in a
standard dose. Firstly, the tissue effect is determined
by the unbound/free drug fraction, and this fraction is
susceptible to gestational changes. Chemotherapeutic
agents are highly protein-bound (paclitaxel >95%,
anthracyclines 50–85%, carboplatin 24–50%) (13).
Gestational dilutional hypoalbuminemia may result
in a higher unbound drug fraction (3). We attempted
to measure the free drug fraction of doxorubicin,
epirubicin and paclitaxel. However, the unbound
fraction was below the lower limit of quantiﬁcation
in most samples at the time of steady state drug
concentrations. Moreover, since relatively small
alterations in free drug concentration can be
expected, a large series of patients is required to
overcome the normal interindividual variability. In
the current series, only in patient 1 could an intrain-
dividual comparative result of the free doxorubicin
concentration be obtained 2 hours after exposure.
The gestational and postpartum free drug fraction
was 25 and 10%, respectively. This ﬁnding indicates
that future research should incorporate free drug
measurements.
Secondly, some drugs show a preferential bind-
ing to tumor tissue (14). Koshiba and colleagues
compared tissue concentrations of paclitaxel and
carboplatin in tumoral and non-tumoral cervical,
endometrial and ovarian tissue. They measured
higher paclitaxel concentrations in tumor tissue
than in normal tissue. For carboplatin no difference
was seen. This difference could probably be explained
by the binding site of the paclitaxel, b-tubulin (vs.
DNA for carboplatin), which might have a higherT
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expression in fast-dividing tumoral cells. Moreover,
the tumor concentration of paclitaxel could be linked
to progression free survival (14). Therefore, measure-
ments of tumoral drug concentrations are preferably
incorporated in future studies.
Given the rarity of cancer during pregnancy, it is
not feasible in the short term to achieve conclusive
data on maternal outcome after chemotherapy during
pregnancy – corrected for the different disease-
related prognostic factors. Currently available surro-
gate markers for tumor toxicity such as bone marrow
toxicity, quantiﬁcation of side effects (e.g. hair loss,
nausea, neutropenic fever) or biomarkers for toxicity
or tumor activity, are either unreliable or still in an
early experimental phase of development (13,15).
A limitation of the present report is the small
number of baboons and patients, which does not
allow to achieve statistically signiﬁcant data. How-
ever, the tendency of ﬁndings is consistent for all
tested drugs. We continue to motivate both pregnant
and nonpregnant women to participate in our studies
in order to increase numbers.
To conclude, these data support the hypothesis
that the physiologic changes of pregnancy alter the
disposition of chemotherapeutic agents resulting in
a decreased plasma drug exposure of standard-
dosed chemotherapy. Further research is warranted
to translate the differences in plasma levels into altera-
tions in tumor concentration and treatment efﬁcacy.
The importance of long-term follow-up with regard to
overall survival of women treated with chemotherapy
during pregnancy is underscored.
In addition, these data support continued research
focusing on the free drug fraction, tissue drug con-
centrations and the maternal outcome.
Acknowledgments
We are very grateful to Gunther Guetens and Sonia
Demarsin for their assistance in the analyses. This
research is supported by Research Foundation-
Flanders (F.W.O.) [Project G. 0358.06], ‘Stichting
tegen kanker [Project SCIE2006-17], Research
Fund-K.U.Leuven [OT/07/053], Clinical Research
Fund University Hospital Gasthuisberg and
Nationaal kankerplan [FOD NKP 29 038]. FA is
clinical researcher for Research Foundation-
Flanders (F.W.O.); KVC is aspirant for Research
Foundation-Flanders (F.W.O.).
Declaration of interest: The authors report no
conﬂicts of interest. The authors alone are responsible
for the content and writing of the paper.
References
1. Undevia SD, Gomez-Abuin G, Ratain MJ. Pharmacokinetic
variability of anticancer agents. Nat Rev Cancer. 2005;5:
447–58.
2. Krauer B, Krauer F, Hytten FE. Drug disposition and phar-
macokinetics in the maternal-placental-fetal unit. Pharmacol
Ther. 1980;10:301–28.
3. Koren G (ed). Maternal-fetal toxicology. A clinician’s guide.
New York: Marcel Dekker Inc., 2001.
4. Wiebe VJ, Sipila PE. Pharmacology of antineoplastic
agents in pregnancy. Crit Rev Oncol Hematol. 1994;16:
75–112.
5. Cardonick E, Iacobucci A. Use of chemotherapy during
human pregnancy. Lancet Oncol. 2004;5:283–91.
6. Garland M, Szeto HH, Daniel SS, Tropper PJ, Myers MM,
Stark RI. Zidovudine kinetics in the pregnant baboon.
J Acquir Immune Deﬁc Syndr Hum Retrovirol. 1996;11:
117–27.
7. Hendrickx AG, Kraemer DC. Reproduction. In:
Hendrickx AG (ed). Embryology of the baboon. Chicago:
University of Chicago Press, 1971. pp. 22–50.
8. Calvert AH, Newell DR, Gumbrell LA, O’Reilly S,
Burnell M, Boxall FE, et al. Carboplatin dosage: prospective
evaluation of a simple formula based on renal function. J Clin
Oncol. 1989;7:1748–56.
9. Quadri KH, Bernardini J, Greenberg A, Laifer S, Syed A,
Holley JL. Assessment of renal function during pregnancy
using a random urine protein to creatinine ratio and
Cockcroft-Gault formula. Am J Kidney Dis. 1994;24:416–20.
10. Lycette JL, Dul CL, Munar M, Belle D, Chui SY,
Koop DR, et al. Effect of pregnancy on the pharmacokinetics
of paclitaxel: a case report. Clin Breast Cancer. 2006;7:
342–4.
11. Stensheim H, Moller B, van Dijk T, Fossa SD. Cause-speciﬁc
survival for women diagnosed with cancer during pregnancy
or lactation: a registry-based cohort study. J Clin Oncol. 2009;
27:45–51.
12. Cardonick E, Dougherty R, Grana G, Gilmandyar D,
Ghaffar S, Usmani A. Breast cancer during pregnancy: mater-
nal and fetal outcomes. Cancer J. 2010;16:76–82.
13. De Vita VJ, Hellman S, Rosenberg S. Cancer principles and
practice of oncology. Philadelphia: Lippincott Williams &
Wilkins, 2001.
14. Koshiba H, Hosokawa K, Mori T, Kubo A, Watanabe A,
Honjo H. Intravenous paclitaxel is speciﬁcally retained in
human gynecologic carcinoma tissues in vivo. Int J Gynecol
Cancer. 2009;19:484–8.
15. Rockett JC, Burczynski ME, Fornace AJ, Herrmann PC,
Krawetz SA, Dix DJ. Surrogate tissue analysis: monitoring
toxicant exposure and health status of inaccessible tissues
through the analysis of accessible tissues and cells. Toxicol
Appl Pharmacol. 2004;194:189–99.
Reduced chemotherapy exposure in pregnancy 1345
A
ct
a 
O
bs
te
t G
yn
ec
ol
 S
ca
nd
 D
ow
nl
oa
de
d 
fro
m
 in
fo
rm
ah
ea
lth
ca
re
.c
om
 b
y 
U
ni
ve
rs
ity
 o
f G
en
t o
n 
06
/1
9/
12
Fo
r p
er
so
na
l u
se
 o
nl
y.
